$CDNA Achieves Significant Milestone Towards CMS Coverage for AlloSure

BRISBANE, Calif., May 04, 2017 — CareDx, Inc. (NASDAQ:CDNA) announces that Palmetto GBA has released a draft local coverage determination (LCD) for AlloSure. AlloSure is the first and only non-invasive test that uses donor derived cell free DNA as a biomarker to directly measure allograft injury and identify the probability of active rejection.

“This marks an important milestone in making AlloSure available to kidney transplant patients,” said Peter Maag, Chief Executive Officer at CareDx. “We are tracking against a commercial launch of AlloSure later in 2017 following the completion of reimbursement discussions. The draft LCD release underscores our leadership position in partnering with the transplant community on novel diagnostic solutions to improve patient management and long-term outcomes.”

The draft local coverage decision was issued following completion of the MolDx (Molecular Diagnostics) Technical Assessment process by Palmetto GBA. During the technical assessment process, subject matter experts and the MolDx team determine if an assay demonstrates clinical utility and fulfills the Centers for Medicare & Medicaid Services (CMS) ‘reasonable and necessary’ criteria. In order to receive favorable review results, the assay must also meet analytical and clinical validity standards.

CMS has awarded Palmetto GBA with the administration of the Molecular Diagnostics Program. The MolDx group at Palmetto has accumulated a wealth of knowledge on the clinical use of high value diagnostics. Other Medicare Administrative Contractors that participate in the Palmetto GBA MolDX Program are expected to also issue local coverage determinations for AlloSure in the near future.

There were over 19,000 kidney transplants in 2016 in the US, but about 20% will experience rejection in the first five years. With a long waiting list to receive a kidney transplant, graft loss is devastating.  “Once kidney disease patients receive a transplant, their quality of life significantly improves,” said Jim Gleason, TRIO National President. “Better diagnostics that support the patient management and rejection detection are needed. The transplant community looks forward to having the AlloSure test available to support those long-term post-transplant life benefits.”

The draft LCD can be found online here: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37265&ContrId=381&ver=6&ContrVer=1&CntrctrSelected=381*1&Cntrctr=381&name=&DocType=AllProposed&s=34%7c48%7c53%7c58&bc=AggAAAQAAAAAAA%3d%3d&

About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients.  CareDx is pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation.

CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs.

For more information, please visit: www.CareDx.com.

Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 filed by us with the SEC on November 14, 2016.  Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Contact
Sasha King, Head of Marketing
T: +1 415-287-2393
E: sking@caredx.com

$AMMA Consummates Atlanta Promotion Deal

Alliance MMA, Inc. (“Alliance MMA” or the “Company”) (NASDAQ:AMMA), a professional mixed martial arts (MMA) company that brings together the best regional productions building the next generation of MMA champions, announced today it has acquired the assets of National Fighting Championship (NFC), which produces professional regional MMA events throughout Georgia and South Carolina.

“We are effectively and systematically continuing to execute our strategy of aggressively acquiring leading regional MMA promotions across the country,” said Robert Haydak, President of Alliance MMA. “The addition of NFC to the Alliance MMA enterprise clearly validates the ongoing success of our business model. Their documented experience in producing outstanding MMA events, and the fact that they have established a solid brand name in Atlanta, one of our remaining targeted top 20 national media markets, makes NFC an ideal fit for Alliance MMA.”

In 2002, at the age of 26, David Oblas formed Undisputed Productions, LLC and became the youngest promoter in the history of fight promotion in Georgia – he is currently the longest running MMA promoter in the state. In 2007, he rebranded Undisputed Productions to National Fighting Championship (NFC). In 2017, Mr. Oblas acquired US Freedom Fighter Championship (USFFC), based in South Carolina, and after rebranding it with the NFC name, will continue to promote MMA events in various South Carolina markets. Undisputed Productions and NFC have promoted a combined total of more than 100 events since 2002, and NFC plans to continue its expansion throughout Georgia and South Carolina.

To date, NFC has promoted fights at a number of venues in Atlanta, and currently produces regional MMA events at Center Stage in Atlanta, Infinite Energy Arena in Duluth, GA, Electric Cowboy in Kennesaw, GA, and the TD Convention Center in Greenville, SC. On July 22 of this year, NFC will host an all-day event at Infinite Energy Arena in Duluth, GA to celebrate its 15-year anniversary, and later this year will promote NFC 100.

“I started promoting professional MMA events because I’m the biggest fan of the sport. After attending shows for years as a member of the Georgia Athletic & Entertainment Commission, I believed I could do better,” said Oblas. “Everything I’ve done since 2002 has been with the mindset of making NFC the best possible experience for the fighters and fans. Joining Alliance MMA is no different. Alliance MMA is providing me with the opportunity to continue delivering the very best regional MMA events in the Southeast to fighters and fans.”

NFC will be the 9^th regional MMA promotion operating under the Alliance MMA umbrella. The Company also promotes regional MMA events through New Jersey-based Cage Fury Fighting Championship (CFFC), Washington-based Combat Games MMA (COGA), Illinois-based Hoosier Fight Club (HFC), Tennessee-based V3 Fights, Maryland-based Shogun Fights, Ohio-based Iron Tiger Fight Series (IT Fight Series), Florida-based Fight Time Promotions, as well as a San Diego-based promotion under the guidance of MMA luminary Eric Del Fierro.

About Alliance MMA, Inc.

Alliance MMA (NASDAQ:AMMA) is a professional mixed martial arts (MMA) company that brings together the best regional productions. Alliance MMA’s mission is to identify and cultivate the next generation of fighters and champions for the Ultimate Fighting Championship (UFC) and other premier MMA promotions.

With some of the world’s leading MMA promotions under the Alliance MMA umbrella, the organization aims eventually to host in excess of 125 events per year, showcasing more than 1,000 fighters. Alliance MMA is also dedicated to generating live original sports media content, attracting an international fan base, and securing major brand sponsorship revenue for live MMA events, digital media, and Alliance MMA fighters.

MMA is the world’s fastest growing sport with worldwide fans of approximately 300 million according to sports marketing research firm Repucom. MMA is a full contact sport that allows a wide range of fighting techniques, including striking and grappling from various martial arts and disciplines including Boxing, Wrestling, Brazilian Jiu Jitsu, Karate and Muay Thai. Professional MMA fights are legal and regulated by state athletic commissions in all 50 states.

Alliance MMA, Inc. was incorporated in 2015 for the purpose of acquiring businesses that engage in the promotion of mixed martial arts (MMA) events. In 2016, the company completed an initial public offering that culminated in a listing on the NASDAQ stock exchange. Alliance MMA is the only mixed martial arts promotion company that is publicly-traded.

For more information visit, www.alliancemma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, those discussed under the heading “Risk Factors” in our registration statement on Form S-1 (Registration No. 333-213166) declared effective by the Securities and Exchange Commission on September 2, 2016. Alliance MMA encourages you to review other factors that may affect its future results in Alliance MMA’s registration statement and in its other filings with the Securities and Exchange Commission.

$LNTH Public Secondary Offering by Selling Stockholders, 3M Shares of Common Stock

Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ:LNTH), today announced an agreement to sell 3,000,000 shares of its common stock to be offered by certain of its existing stockholders (the “Selling Stockholders”), pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) on Form S-3. The Company will not receive any proceeds from the sale of shares by the Selling Stockholders. Credit Suisse Securities will act as underwriter for the offering.

A shelf registration statement (including a prospectus) relating to the offering of common stock was filed with the SEC on December 12, 2016 (and became effective on January 4, 2017). Before you invest, you should read the prospectus included in the registration statement and the documents incorporated by reference therein as well as the prospectus supplement related to this offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus related to the offering may also be obtained by contacting Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, New York, 10010, or by calling (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com.

The offering of these securities will be made only by means of a prospectus supplement and the accompanying prospectus.

This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer to buy the securities may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date of the shelf registration statement.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada.

Safe Harbor
This press release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the offering. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “should,” “could,” “predicts,” “targets,” “hopes” or, in each case, their negatives or other variations or comparable terminology. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future, including risks and uncertainties relating to the consummation of the proposed offering by the Selling Stockholders and the risks identified, or incorporated by reference, in the prospectus supplement or accompanying prospectus.

Lantheus Holdings, Inc.
Corporate Communications:
Meara Murphy, 978-671-8508
or
Investor Relations:
Gary F. Santo, Jr., 978-671-8960

$NYMX Files For Marketing Approval For Fexapotide Triflutate in Europe

HASBROUCK HEIGHTS, N.J., May 03, 2017 — Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain. This first filing for Fexapotide Triflutate is for the indication of treatment of the symptoms of BPH (benign prostatic hyperplasia; prostate enlargement).

“Fexapotide has the real potential to alter the way BPH will be treated in the future. There is a major unmet medical need for a safe and efficacious treatment method for the many men who suffer from this age-related malady,” said Dr. Paul Averback, CEO of Nymox.

“This first filing represents a major corporate milestone for the development of Fexapotide. We are extremely pleased to achieve this milestone which is based on intensive work carried out by our teams and many expert collaborators over the past 15 years,” Dr. Averback added.

Erik Danielsen, Nymox’s CFO added, “Going forward, we expect to announce further regulatory filings for approval in additional important jurisdictions around the world as well as corporate initiatives supporting our pre-commercialization efforts.  We now plan to significantly step up our communication programs with both the medical as well as the financial communities. Today’s important step forward will be followed up by additional strategic business development activities.”

Fexapotide has been in development by Nymox for 15 years. Clinical trials have shown long-term symptomatic improvement, long-term reduction in the need for BPH surgery, long-term reduced prostate cancer risk, and an excellent long-term safety profile with no sexual side effects in comparison to available drug treatments. Fexapotide Triflutate is administered at an office visit and consists of a single painless injection that takes a few minutes or less, with no requirements of anesthesia, or analgesia or catheterization. There are none of the typical sexual and other distressing side effects seen with conventional BPH treatments.

BPH is highly prevalent in middle aged and elderly men, affecting millions of men world-wide. Existing medical treatments for BPH generally provide temporary relief only, and are commonly discontinued by patients due to side effects and little efficacy. Surgical treatments are effective but often have permanent retrograde ejaculation as a result, and other problems and risks are associated.

Nymox will hold a teleconference call for shareholders next week. Further details regarding the teleconference will be announced in advance of the call.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.

Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com

$STRP Board Deems $135.96 Per Share Acquisition Offer a “Superior Proposal”

Straight Path Communications Inc. (“Straight Path”) (NYSE MKT:STRP) announced today that the Straight Path Board of Directors (the “Straight Path Board”) determined that a revised offer from a multi-national telecommunications company (the “Bidder”) to acquire 100% of the issued and outstanding shares of Straight Path for $135.96 per share (reflecting an enterprise value of approximately $2.3 billion), which will be paid in Bidder stock in an all-stock transaction constitutes a “Superior Proposal” as defined in Straight Path’s previously announced definitive agreement and plan of merger with AT&T Inc. (“AT&T”) (NYSE:T) and Switchback Merger Sub Inc., dated as of April 9, 2017 (the “AT&T Merger Agreement”). The Bidder previously submitted an unsolicited offer on April 24, 2017 to acquire 100% of the issued and outstanding shares of Straight Path for $104.64 per share (reflecting an enterprise value of $1.8 billion), which has been superseded by the revised offer announced today.

Under the terms of the AT&T Merger Agreement, AT&T agreed to acquire Straight Path in an all-stock transaction in which Straight Path stockholders would receive $95.63 per share (reflecting an enterprise value of $1.6 billion), which would be paid using AT&T stock.

Straight Path has notified AT&T of the Straight Path Board’s determination and, pursuant to the AT&T Merger Agreement, AT&T has the option for the next three (3) business days (the “Negotiation Period”) to negotiate a possible amendment of that agreement to match or exceed the Bidder’s offer. Straight Path is required, and intends to, negotiate in good faith with AT&T during the Negotiation Period. Straight Path is not permitted to enter into the Bidder’s merger agreement or to change its recommendation in favor of the AT&T transaction unless, at the end of the Negotiation Period, the Straight Path Board determines that the Bidder’s offer continues to constitute a “Superior Proposal” and satisfies certain other requirements under the AT&T Merger Agreement. The Bidder has stated that its offer will remain outstanding until 11:59 p.m. New York City time on May 8, 2017.

Under the AT&T Merger Agreement, Straight Path is required to pay a $38 million termination fee to AT&T if the Straight Path Board terminates the AT&T Merger Agreement in order to enter into an agreement with the Bidder. The Bidder has agreed to pay the termination fee to AT&T on Straight Path’s behalf in such event. Straight Path would be required to repay the Bidder for the AT&T termination fee under certain circumstances in connection with a termination of the Bidder’s merger agreement.

At this time, Straight Path remains subject to the AT&T Merger Agreement and the Straight Path Board has not changed its recommendation in support of the AT&T transaction, the existing AT&T Merger Agreement, or its recommendation that Straight Path’s stockholders adopt the AT&T Merger Agreement. There can be no assurances that a transaction with the Bidder will result from the Bidder’s offer, or that any other transaction will be consummated. There can be no assurance that AT&T will seek to negotiate with Straight Path or will make a revised offer.

About Straight Path Communications Inc.

Straight Path (NYSE MKT:STRP) holds an extensive portfolio of 39 GHz and 28 GHz wireless spectrum licenses. Straight Path is developing next generation wireless technology through its Straight Path Ventures subsidiary. Straight Path holds licenses and conducts other business related to certain patents through its Straight Path IP Group subsidiary. Additional information is available on Straight Path’s websites.

Corporate: www.straightpath.com.

Spectrum: www.straightpath39.com.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

Straight Path plans to file with the SEC and mail to its stockholders a Proxy Statement/Prospectus in connection with the proposed transaction. THE PROXY STATEMENT/PROSPECTUS WILL CONTAIN IMPORTANT INFORMATION ABOUT AT&T, STRAIGHT PATH, THE PROPOSED TRANSACTION AND RELATED MATTERS. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS CAREFULLY WHEN THEY BECOME AVAILABLE. Investors and security holders will be able to obtain free copies of the Proxy Statement/Prospectus and the other documents filed with the SEC by Straight Path through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of the Proxy Statement/Prospectus by phone, e-mail or written request by contacting the investor relations department of Straight Path at the following:

PARTICIPANTS IN THE SOLICITATION

Straight Path and its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transactions contemplated by the AT&T Merger Agreement. Information regarding Straight Path’s directors and executive officers is contained in Straight Path’s Form 10-K for the year ended July 31, 2016 and its proxy statement dated November 22, 2016, which are filed with the SEC. A more complete description will be available in the Proxy Statement/Prospectus.

Safe Harbor

In this press release, all statements that are not purely about historical facts, including, but not limited to, those in which we use the words “believe,” “anticipate,” “expect,” “plan,” “intend,” “estimate, “target” and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors, including, but not limited to, those described in our Annual Report on Form 10-K for the fiscal year ended July 31, 2016 and our other periodic filings with the SEC (under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”). We are under no obligation, and expressly disclaim any obligation, to update the forward-looking statements in this press release, whether as a result of new information, future events or otherwise.

No Offer or Solicitation

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

$ESES Awarded New Long-Term Contract — Value Should Exceed $50 million

$PIRS & $AZN Collaborate, Anticalin-Based Inhaled Treatments

$WKHS & $R Form Partnership Over EV & Drone Package Delivery

Ryder System, Inc. (NYSE:R), a leader in commercial fleet management, dedicated transportation, and supply chain solutions, announced today that the Company will be the strategic service partner for Workhorse Group Inc. (NASDAQ:WKHS), an Ohio-based battery-electric truck and drone manufacturer. Ryder will be the exclusive maintenance provider for Workhorse’s entire light- and medium-duty range-extended electric vehicle fleet in North America and will provide a combination of warranty and maintenance services as part of Ryder’s SelectCare fleet maintenance portfolio. Ryder will also serve as the primary distributor in North America for Workhorse’s E-100^® and E-GEN^® range-extended medium-duty vehicles, as well as the W-15 electric pickup truck being unveiled later today during the Advanced Clean Transportation (ACT) Expo.

Tweet This: @RyderSystemInc to be strategic service partner for @Workhorse_Group electric vehicles, unlocking the full potential of their innovative range-extended fleet.

Through its partnership with Workhorse, Ryder expands its leadership in advanced vehicle technology, strengthening the Company’s ability to provide customers with the most flexibility, choice, and control in fleet management, as well as innovative solutions to help them reach their sustainability goals. The new partnership will provide Workhorse with access to a superior level of maintenance solutions at hundreds of Ryder service locations throughout North America. Through Ryder SelectCare maintenance, Workhorse will be able to maximize uptime, lower costs, and keep their customers’ businesses moving. Through this strategic partnership, Ryder and Workhorse will work together in promoting energy efficiency and innovation in the industry.

“Ryder is pleased to partner with Workhorse,” said Dennis Cooke, President, Global Fleet Management Solutions for Ryder. “We commend them for their leadership and decision to partner exclusively with Ryder for their range-extended electric commercial vehicle maintenance needs. This relationship will help make electric commercial vehicles more affordable and reliable, so more businesses can take advantage of their environmental and efficiency benefits.”

Workhorse, an American technology company focused on providing sustainable and cost-effective solutions to the commercial transportation industry, manufactures and sells the E-100 battery-electric and E-GEN range-extended electric vehicles. The Workhorse E-100 and E-GEN medium-duty vehicles are currently available to customers in North America and the W-15 electric pickup truck is expected to be in production in late 2018. The company also manufactures fully integrated truck-launched, FAA-compliant unmanned aerial systems (UAS) delivery drones.

“With Ryder, we can bring our leading-edge range-extended electric vehicle technology to a larger base of businesses that are looking to improve efficiencies, save on fueling costs, and get better performance from their fleets,” said Stephen Burns, Workhorse founder and CEO. “Ryder is the global leader in commercial fleet management, yet they’re incredibly agile and forward thinking, especially in their approach to transportation innovations and advanced vehicle technologies. We are proud to rely on Ryder to meet the unique service requirements of our electric vehicle fleet, including our newest W-15 model, the first plug-in, battery-electric range-extended pickup truck built from the ground up by a U.S. original equipment manufacturer.”

About Ryder

Ryder is a FORTUNE 500^® commercial fleet management, dedicated transportation, and supply chain solutions company. The Company offers nationwide access to state-of-the-art service facilities, 5,900 certified technicians, and a dedication to superior repair quality, safety, speed, and full visibility. Ryder offers a wide range of maintenance products for all vehicle types, delivering flexibility around the level of maintenance that companies require in order to keep their fleet running properly throughout its life span.

In 2016, Ryder further expanded its advanced vehicle technology portfolio and continued its leadership in the market with the announcement that the Company would be the sole maintenance and distribution partner in North America for the hydrogen fuel cell Nikola One semi-truck. Nikola’s hydrogen fuel cell semi-truck is expected to have a range of 800-1,200 miles and achieve approximately 15-20 mpg with zero emissions. This partnership with Nikola aligns with Ryder’s strategic priorities to provide customers with the most flexibility, choice, and control in fleet management. Ryder’s market leadership in operating advanced vehicle technologies in commercial truck applications also includes the Company’s natural gas vehicle (NGV) and maintenance solutions offering. Ryder currently has more than 100 million miles of NGV operations, 22 NGV maintenance facilities, and more than 6,200 NGV trained maintenance and support personnel across the Company’s North American service network.

Ryder is continually monitoring emerging fleet technologies and works closely with the technology providers and equipment manufacturers building innovative features to provide feedback around functionality, usability, and adaptability. The Company offers state-of-the-art service facilities, 5,900 certified technicians, and a dedication to superior repair quality, safety, speed, and full visibility.

Ryder’s stock (NYSE:R) is a component of the Dow Jones Transportation Average and the Standard & Poor’s 500 Index. The Company has been named among FORTUNE’s World’s Most Admired Companies, and has been recognized for its industry-leading practices in third-party logistics, environmentally-friendly fleet and supply chain solutions, and world-class safety and security programs. Inbound Logistics magazine has included Ryder in its “Green Partners” listing for eight years in a row. Ryder was also recognized by the U.S. Environmental Protection Agency (EPA) with a 2014 SmartWay Affiliate Challenge award and SmartWay Excellence Awards in 2014 and 2013. Ryder is a charter member of the NGV Fleet Forum and a member of the Department of Energy’s National Clean Fleets partnership. Ryder is also a recipient of the 2011 NGV Achievement Award. A member of the American Red Cross Disaster Responder Program, Ryder is proud to support national and local disaster preparedness and response efforts. For more information, visit www.ryder.com, and follow us on our Online Newsroom and social media pages: Facebook, LinkedIn, Twitter, Instagram, and YouTube.

About Workhorse Group Inc.

Workhorse is a technology company focused on providing sustainable and cost-effective solutions to the commercial transportation sector. As an American original equipment manufacturer, we design and build high-performance battery-electric vehicles including trucks and aircraft. We also develop cloud-based, real-time telematics performance monitoring systems that are fully integrated with our vehicles and enable fleet operators to optimize energy and route efficiency. All Workhorse vehicles are designed to make the movement of people and goods more efficient and less harmful to the environment.

Note Regarding Forward-Looking Statements: Certain statements and information included in this news release are “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current plans and expectations and are subject to risks, uncertainties and assumptions. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements including those risks set forth in our periodic filings with the Securities and Exchange Commission. New risks emerge from time to time. It is not possible for management to predict all such risk factors or to assess the impact of such risks on our business. Accordingly, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

$CYAD Grants Novartis Non-Exclusive License, TCR-deficient CAR-T Patents

MONT-SAINT-GUIBERT, Belgium, May 02, 2017 — Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s US patents for the production of allogeneic CAR-T cells. This license agreement is related to two targets currently under development by Novartis

The agreement includes Celyad’s intellectual property rights under United States Patent No. 9,181,527 related to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR) deficient and express a Chimeric Antigen Receptor (CAR). The granted claims are not limited to specific CARs or specific methods of generating allogeneic CAR T- cells, such as genome editing or genetic engineering.

Under the terms of the agreement Celyad receives an upfront payment and is eligible to receive success based clinical, regulatory and commercial milestone payments. If all success based milestones are achieved, Celyad is eligible to receive payments, including the upfront payment, totalling $96 million. In addition, Celyad will receive single digit royalties based on net sales of the licensed target associated products. Novartis has the option to extend the agreement to additional targets and/or to convert its license into an exclusive license. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

Celyad will not be involved in the development of Novartis’ CAR-T cells. Celyad will continue to focus on the development of its CAR-T pipeline, including its allogeneic NKR-2 T-cell immunotherapy in the EU and US territories and in collaboration with Ono Pharmaceuticals, its partner in Japan, Taiwan and Korea.

Dr. Christian Homsy, CEO of Celyad, said: “This non-exclusive agreement with Novartis recognizes the importance of our IP for companies developing allogeneic CAR-T therapies.”

About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized cell- based therapies. The Company utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, the CAR-T NKR-2, has been evaluated in a single dose -escalation Phase I clinical trial to assess the safety and feasibility of CAR-T NKR-2 cells in patients suffering from AML or MM. This Phase I study was successfully completed in September 2016. Celyad was founded in 2007 and is based in Mont-Saint Guibert, Belgium, and Boston, Massachusetts. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on NASDAQ Global Market, all under the ticker symbol CYAD.

For more information about Celyad, please visit: www.celyad.com

For more information, please contact:

To subscribe to Celyad’s newsletter, visit www.celyad.com
Follow us on LinkedIn & Twitter @CelyadSA

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward looking statements, including statements about the potential safety and feasibility of CAR-T NKR-2 cell therapy, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These forward looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including risks associated with conducting clinical trials; the risk that safety, bioactivity, feasibility and/or efficacy demonstrated in earlier clinical or pre-clinical studies may not be replicated in subsequent studies; risk associated with the timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase I clinical trial for CAR-T NKR-2; risks associated with the satisfaction of regulatory and other requirements; risks associated with the actions of regulatory bodies and other governmental authorities; risks associated with obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; risks associated with competition from others developing products for similar uses; risks associated with our ability to manage operating expenses; and risks associated with our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. A further list and description of these risks, uncertainties and other risks can be found in the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F filed with the SEC on April 8, 2016 and future filings and reports by the Company. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

$NTNX Firstnet Offers Hybrid Cloud Services Powered Exclusively by Nutanix

Nutanix (NASDAQ: NTNX), a leader in enterprise cloud computing, has announced an agreement with Leeds-based managed service provider, Firstnet Solutions, to offer customers a choice of flexible hybrid cloud services based on the Nutanix Enterprise Cloud Platform.

An established provider of managed services in the North of England, Firstnet Solutions recently formed a new entity, Firstnet Data Centres, which opened its first datacentre in Leeds. Aspiring to be the first dedicated Tier III datacentre in its region, it gives customers a choice of traditional co-location facilities alongside a new mix of managed hosting, virtual desktop and cloud services. These new services will be based entirely on the Nutanix Enterprise Cloud Platform, chosen after exhaustive research and competitive analysis.

“We spent months looking at both traditional 3-tier and hyperconverged infrastructure alternatives,” explains Paul Straton, Head of Enterprise Technologies at Firstnet, “none of which matched the Nutanix Enterprise Cloud Platform, which simply re-writes all the rules. It is less complicated and much easier to manage than anything else on the market, featuring a self-healing architecture. It is also hugely scalable and able to deliver the services customers need to build a hybrid cloud infrastructure.”

Key differentiators were the single Nutanix Prism management pane for both compute and storage resources, plus the hypervisor neutral virtualisation capabilities of the Nutanix platform. Together, these will enable Firstnet to offer customers immediate managed hosting, quickly followed by VDI services using the built-in virtualisation solution, Nutanix AHV, which is included at no additional cost with every Nutanix deployment. In VDI environments where the costs per desktop are very important, the ability to use a robust and certified hypervisor with zero license costs is a great benefit.

As a Nutanix partner, Firstnet will provide customers with a complete end-to-end hybrid cloud solution based on the Nutanix Enterprise Cloud Platform. Customers using Nutanix for their on-premise infrastructure can leverage the built-in replication, backup, and DR functions by connecting to the Nutanix clusters hosted by Firstnet.

“We are delighted to have Firstnet Solutions as both a customer and a partner,” commented Mark Lewis, Senior Director of EMEA Marketing at Nutanix, “demonstrating the ability to build scale-out infrastructures delivering the advantages of the public cloud but using the Nutanix Enterprise Cloud Platform on-premise and in a service provider’s datacentre.”

Since the opening of the datacentre in April, a number of existing customers have already signed up to migrate to the new Nutanix environment. The company also has ambitious plans to offer Nutanix-powered backup and recovery services from a dedicated disaster recovery suite complete with offsite office facilities, similarly, sited within the new Leeds datacentre.

About Nutanix

Nutanix makes infrastructure invisible, elevating IT to focus on the applications and services that power their business. The Nutanix enterprise cloud platform leverages web-scale engineering and consumer-grade design to natively converge compute, virtualisation and storage into a resilient, software-defined solution with rich machine intelligence. The result is predictable performance, cloud-like infrastructure consumption, robust security, and seamless application mobility for a broad range of enterprise applications. Learn more at www.nutanix.com or follow us on Twitter @nutanix.

© 2017 Nutanix, Inc. All rights reserved. Nutanix is a trademark of Nutanix, Inc., registered in the United States and other countries. All other brand names mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s).

$RCII Engaged Capital Releases Presentation to Rent-A-Center Stockholders

Engaged Capital, LLC (together with its affiliates, “Engaged Capital”), an investment firm specializing in enhancing the value of small and mid-cap North American equities with a 20.5% economic exposure to Rent-A-Center, Inc. (“RCII” or the “Company”) (NASDAQ:RCII), announced today that it has released a presentation to RCII stockholders highlighting RCII’s poor corporate governance which has resulted in significant stockholder value destruction. The presentation is available at http://www.engagedcapital.com/press/RCII-Presentation.pdf.

In its presentation to stockholders, Engaged Capital outlines how it believes that RCII’s board of directors (the “Board”) has not represented the interests of stockholders due to its corporate governance flaws, which in addition to the over 20-year tenure of CEO, Chairman and Co-Founder Mark Speese, includes a classified Board structure and average director tenure exceeding ten years. Engaged Capital firmly believes there is an opportunity to significantly increase stockholder value, but change is needed.

“Under the current Board, Rent-A-Center has materially underperformed the market and its peers over the short, medium and long-term. It is time to replace the directors responsible for this abysmal performance and who have refused to evaluate all alternatives to create value for stockholders. We believe there is an opportunity to increase stockholder value by 50% to 100%. Our highly-qualified nominees, who are fully aligned with stockholders’ interests, have the experience and determination to evaluate all options and pursue the strategy that will drive the highest return for all stockholders. The time for change at Rent-A-Center is NOW!” said Glenn W. Welling, the Founder and Chief Investment Officer of Engaged Capital.

IT IS TIME TO HOLD THE RCII BOARD ACCOUNTABLE

VOTE THE BLUE ENGAGED CAPITAL PROXY CARD FOR ALL THREE ENGAGED CAPITAL NOMINEES TODAY

If you have any questions, or require assistance with your vote, please contact Saratoga Proxy Consulting LLC, toll- free at (888) 368-0379, call direct at (212) 257-1311 or email: info@saratogaproxy.com

About Engaged Capital:

Engaged Capital, LLC (“Engaged Capital”) was established in 2012 by a group of professionals with significant experience in activist investing in North America and was seeded by Grosvenor Capital Management, L.P., one of the oldest and largest global alternative investment managers. Engaged Capital is a limited liability company owned by its principals and formed to create long-term shareholder value by bringing an owner’s perspective to the managements and boards of undervalued public companies. Engaged Capital’s efforts and resources are dedicated to a single investment style, “Constructive Activism” with a focus on delivering superior, long-term, risk-adjusted returns for investors. Engaged Capital is based in Newport Beach, California.

$MOC Announces $80M Contract Award

HERNDON, Va., May 02, 2017 — Command Security Corporation (NYSE MKT:MOC) announced today that the Company has received the award of a three-year contract to provide security services with a major on-line retailer. This award is in addition to current services by the Company to this customer. Total annual revenues associated with this award are estimated to be approximately $27.0 million or approximately $80.0 million over the three-year term. The work which is planned to begin in June 2017, will be performed at approximately 60 locations across the Northeast and Midwest regions of the United States.

“This is a significant acknowledgment of the effort and commitment we have delivered to our business partner. Our team has demonstrated great dedication and teamwork with our customer at all of our sites,” said Jeff Jordan – Program Manager and Vice President.

About Command Security Corporation

Command Security Corporation and its Aviation Safeguards division provide uniformed security officers and aviation security services to commercial, financial, industrial, aviation and governmental customers throughout the United States. As our credo states “Securing All You Value,” we safeguard against theft, fraud, fire, intrusion, vandalism and the many other threats that our customers are facing today. By partnering with each customer, we design programs customized to meet their specific security needs and address their particular concerns. We bring years of expertise, including sophisticated systems for hiring, training, supervision and oversight, backed by cutting-edge technology, to every situation that our customers face involving security. Our mission is to enable our customers to operate their businesses without disruption or loss, and to create safe environments for their employees. For more information concerning our company, please refer to our website at www.commandsecurity.com.

Forward-Looking Statements

This announcement by Command Security Corporation (referred to herein as the “Company”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and within the meaning of the Private Securities Litigation Reform Act of 1995 about the Company that are based on management’s assumptions, expectations and projections about the Company. Such forward-looking statements by their nature involve a degree of risk and uncertainty. The Company cautions that actual results of the Company could differ materially from those projected in the forward-looking statements as a result of various factors, including but not limited to the factors described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2016, and the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, each of which has been filed with the Securities and Exchange Commission, and such other risks disclosed from time to time in the Company’s periodic and other reports filed with the Securities and Exchange Commission. You should consider the areas of risk described above in connection with any forward-looking statements that may be made by the Company. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any additional disclosures the Company makes in proxy statements, quarterly reports on Form 10-Q, annual reports on Form 10-K and current reports on Form 8-K filed with the Securities and Exchange Commission, which are publicly available at the Securities and Exchange Commission’s website at www.sec.gov/edgar.shtml.

COMPANY CONTACT:
N. Paul Brost
Chief Financial Officer
Command Security Corporation
703-464-4735

$AMMA Hosts First Fight in Philadelphia in 2017

Alliance MMA, Inc. (“Alliance MMA” or the “Company”) (NASDAQ: AMMA), a professional mixed martial arts (MMA) company that brings together the best regional productions building the next generation of MMA champions, is promoting Cage Fury Fighting Championships (CFFC) 65 at the 2300 Arena in Philadelphia on Saturday, May 20^th.

“CFFC returns to the city of Brotherly Love after a successful San Diego event in March,” said Robert Haydak, President of Alliance MMA. “We are looking forward to CFFC 65 because this event provides local fighters with the best opportunities to develop their skills and advance to the next level of competition.”

CFFC 65 features three title fights including Anton Berzin vs. Jamelle Jones for the inaugural light heavyweight title and Joe Lowry vs. Mike Pope for the lightweight title. The main event features “Phighter” Sean Brady vs. Tanner Saraceno for the vacant welterweight title. Brady is the top northeast prospect and comes back after battling an injury to face Saraceno, the CFFC 63 winner and WWE’s “Tough Enough” contestant.

“Since joining Alliance MMA our fighters have a stronger platform to reach the next level of competition,” said Devon Mathiesen, General Manager of CFFC. “We have a lot of talented fighters on the card this time around including Philadelphia fighters Sean Brady, Anton Berzin and Joseph Lowry.”

Tickets for CFFC 65 can be purchased at http://cffc.tv/tickets/cffc-65.

About Alliance MMA, Inc.

Alliance MMA (NASDAQ:AMMA) is a professional mixed martial arts (MMA) company that brings together the best regional productions. Alliance MMA’s mission is to identify and cultivate the next generation of fighters and champions for the Ultimate Fighting Championship (UFC) and other premier MMA promotions.

With some of the world’s leading MMA promotions under the Alliance MMA umbrella, the organization aims eventually to host in excess of 125 events per year, showcasing more than 1,000 fighters. Alliance MMA is also dedicated to generating live original sports media content, attracting an international fan base, and securing major brand sponsorship revenue for live MMA events, digital media, and Alliance MMA fighters.

MMA is the world’s fastest growing sport with worldwide fans of approximately 300 million according to sports marketing research firm Repucom. MMA is a full contact sport that allows a wide range of fighting techniques, including striking and grappling from various martial arts and disciplines including Boxing, Wrestling, Brazilian Jiu Jitsu, Karate and Muay Thai. Professional MMA fights are legal and regulated by state athletic commissions in all 50 states.

Alliance MMA, Inc. was incorporated in 2015 for the purpose of acquiring businesses that engage in the promotion of mixed martial arts (MMA) events. In 2016, the company completed an initial public offering that culminated in a listing on the NASDAQ stock exchange. Alliance MMA is the only mixed martial arts promotion company that is publicly-traded.

For more information visit, www.alliancemma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, those discussed under the heading “Risk Factors” in our registration statement on Form S-1 (Registration No. 333-213166) declared effective by the Securities and Exchange Commission on September 2, 2016. Alliance MMA encourages you to review other factors that may affect its future results in Alliance MMA’s registration statement and in its other filings with the Securities and Exchange Commission.

$CHRS Management to Present at Two Investor Healthcare Conferences in May

REDWOOD CITY, Calif., May 01, 2017  — Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.

• A fireside chat is scheduled at Deutche Bank’s 42^nd Annual Health Care Conference on Wednesday, May 3^rd at 10:40 a.m. EDT taking place in Boston, MA.
• A company presentation is scheduled at the Bank of America/Merrill Lynch Healthcare Conference on Thursday, May 18^th at 8:40 a.m. PDT taking place in Las Vegas, NV.

The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.

About Coherus BioSciences, Inc.

Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.

CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
pobrien@coherus.com
+1 (650) 649-3527

$VTGN Largest Stockholder Signs 6-Month Lock-Up Agreement

$MYSZ SizeUp App Gains Traction Among Consumers

$RTNB Sells IPSA’s Investigative Due Diligence Practice

COLORADO SPRINGS, Colo., May 1, 2017  — root9B Holdings, Inc. (Nasdaq: RTNB) (“RTNB”) today announced that it has sold the Investigative Due Diligence Practice (“IDDP”) of its wholly-owned subsidiary IPSA International Services, Inc. (“IPSA”) to Exiger Canada, Inc. (“Exiger”) for total consideration of $6 million and up to an additional $4 million by way of a three-year earn-out based on the achievement by IDDP of certain performance targets.  Proceeds will be reduced by a Working Capital Adjustment, currently estimated to be in excess of $1.0m.

The IDDP includes the sale of the stock of IPSA’s Canadian subsidiary (IPSA International, Inc. Canada) located in Vancouver, BC and IPSA’s London, Hong Kong and Miami offices, contracts and employees. For the past 15 years, IPSA’s IDDP has provided services in matters of multi-jurisdictional corruption, bribery and due diligence investigations.  The IDDP also performs due diligence related to travel, employment and settlement including for immigration, citizenship & visas; and is considered an industry pioneer in work related to citizenship by investment due diligence where it is considered a trusted leader by many of the largest and fastest growing programs operating in the world today.

“We have made measurable progress in re-positioning RTNB’s business to that of a pure-play cybersecurity company,” said Joseph J. Grano, Jr., Chairman and CEO of RTNB.  “The sale of our IDDP, along with our previously announced non-core divestitures, strengthens RTNB’s overall financial positon and provides additional capital to fund the growth of our cybersecurity operations.  We have great confidence in our team of cybersecurity professionals that is led by Eric Hipkins, the founder and CEO of our root9B LLC subsidiary who will become CEO of RTNB on May 25, 2017.”

“We continue to execute against our previously announced set of strategic initiatives, and this transaction is another meaningful step in that regard,” said Dan Wachtler, President and COO of RTNB. “Kim Marsh has been my partner for nearly 15 years, and he and his team have built a great business for IPSA. We are confident however that each of us will be in a better position to grow our two distinct businesses as separate companies. While we still need to complete the divestiture of our remaining Anti-Money Laundering business, we can now more fully focus our internal resources on growing our cyber business and delivering long-term value to our shareholders.”

About root9B
Ranked as the #1 Cybersecurity company for 2016 by Cybersecurity Ventures, root9B stands in defiance of the unwanted human presence within our clients’ networks by attacking the root of the problem—the adversary’s ability to gain entry and remain undetected. root9B’s application of advanced technology developed through cutting-edge R&D and engineering and refined through relevant, hands-on training is revolutionary. root9B combines next generation technology, tactics development, specialty tools, and deep mission experience. root9B personnel leverage their extensive backgrounds in the U.S. Intelligence Community to conduct advanced vulnerability analysis, penetration testing, digital forensics, incident response, Industrial Control System (ICS) security, and HUNT (Active Adversary Pursuit) engagements on networks worldwide. For more information, visit www.root9B.com.

About root9B Holdings, Inc.
root9B Holdings is a leading provider of Cybersecurity and Regulatory Risk Mitigation Services. Through its wholly owned subsidiaries root9B, Business Advisory Services and IPSA International Services, Inc., the Company delivers results that improve productivity, mitigate risk and maximize profits. Its clients range in size from Fortune 100 companies to mid-sized and owner-managed businesses across a broad range of industries including local, state and government agencies. For more information, visit www.root9bholdings.com

About Exiger
Exiger is a global regulatory and financial crime, risk and compliance company.  Exiger arms financial institutions, multinational corporations and governmental agencies with the practical advice and technology solutions they need to prevent compliance breaches, respond to risk, remediate major issues and monitor ongoing business activities.  Exiger works with clients worldwide to assist them in effectively managing their critical challenges while developing and implementing the policies, procedures and programs needed to create a sustainable compliance environment.  A global authority on regulatory compliance, the company also oversees some of the world’s most complex court-appointed and voluntary monitorships in the private and public sectors, including the monitorship of HSBC. Exiger has four principal business units being: Exiger Advisory; Exiger Analytics; Exiger Diligence and Exiger Insight 3PM.  Exiger operates through offices in New York City, Silver Spring (DC Metro), London, Hong Kong, Toronto and Singapore. For more information, visit www.exiger.com.

Forward Looking Statements
Certain statements contained in this press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements are based on the Company’s current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive and/or regulatory factors, and other risks and uncertainties affecting the operation of the Company’s business. These risks, uncertainties and contingencies are indicated from time to time in the Company’s filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. Further, investors should keep in mind that the Company’s financial results in any particular period may not be indicative of future results.  The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

$SPAN Agrees to Be Acquired by Savaria

Span-America Medical Systems, Inc. (“Span-America”) (NASDAQ:SPAN) announced today that it has reached an agreement to be acquired by Savaria Corporation, an Alberta, Canada corporation (“Savaria”) (TSX:SIS). Savaria intends to acquire Span-America by way of an all-cash tender offer for $29 per share, or approximately $80.2 million. The transaction is expected to close in the second calendar quarter of 2017.

Tom Henrion, Chairman of Span-America’s board of directors, said, “The Board of Directors of Span-America unanimously approved the proposed acquisition of Span-America by Savaria. The proposed all-cash tender offer of $29 per share represents an immediate and substantial cash value as well as a significant premium over our stock price, and we believe it fully values the company for our shareholders. Savaria’s offer reflects the value that our management and employee team has created for our shareholders. All of Span-America’s board members and senior managers have agreed to tender their shares in the tender offer.”

Founded in 1979, Savaria provides accessibility solutions for the elderly and physically challenged to increase their mobility and independence. Savaria designs, manufactures, distributes and installs accessibility equipment, such as stair lifts for straight and curved stairs, vertical and inclined wheelchair lifts, elevators for home and commercial use, as well as patient lifts. In addition, it converts and adapts vehicles to be wheelchair accessible. It also operates a network of franchisees and corporate stores through which new and recycled accessibility equipment is sold and, in certain locations, vehicle conversions are performed. Savaria records close to 60% of its revenue outside Canada, primarily in the United States. It operates a sales network of some 400 retailers and affiliates in North America and employs some 500 people. Its principal places of business are located in Laval, Quebec, Brampton, Ontario, and Huizhou, China.

Structure and Terms

Under the terms of the transaction, Span-America shareholders will receive $29 in cash per share. This represents a premium of 33% to Span-America’s closing share price on NASDAQ on April 28, 2017, the last full trading day prior to the announcement date of the Transaction, and a premium of 33% to Span-America’s 20-day volume weighted average closing price, calculated as at April 28, 2017. Savaria has indicated that it will finance the transaction with cash on hand, a financing commitment from National Bank of Canada and a Canadian equity private placement of subscription receipts.

The transaction is subject to customary closing conditions, including receipt of two-thirds of Span-America’s shares on a fully diluted basis in a tender offer to Span-America’ shareholders. All of the members of Span-America’s board of directors and its senior officers have entered into tender support agreements with Savaria committing, subject to certain conditions and exceptions, to tender (without a right of withdrawal) all of their Span-America shares, constituting in aggregate approximately 15.9% of its outstanding shares. Following the successful completion of the tender offer, Savaria will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price per share as that payable under the offer. The transaction is expected to close in the second calendar quarter of 2017.

About Span-America Medical Systems, Inc.

Span-America manufactures and markets a comprehensive selection of pressure management products for the medical market, including Geo-Matt®, PressureGuard®, Geo-Mattress®, Custom Care®, Span+Aids®, Isch-Dish®, Risk Manager® and Selan® products. Through our wholly-owned subsidiary Span Medical Products Canada Inc., we manufacture and market the Encore®, Advantage and Rexx beds as well as related in-room furnishing products for the long-term care market. We also supply custom foam and packaging products to the consumer and industrial markets. Span-America’s stock is traded on The NASDAQ Global Market under the symbol “SPAN.” For more information, please visit www.spanamerica.com.

Advisors

Robert W. Baird & Co. served as Span-America’s financial advisors and Wyche, P.A. served as Span-America’s legal counsel for the transaction.

Investor Conference Call

Span-America will host an investor conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, May 2, 2017. For investors or analysts who want to participate during the call, a live broadcast of the conference call will be available online at www.spanamerica.com under Investor Relations on the About Us tab. The online replay will follow immediately and continue for 30 days.

Important additional information will be filed with the U.S. Securities and Exchange Commission

This announcement is not a recommendation, an offer to purchase, or a solicitation of an offer to sell shares of Span-America stock. Savaria has not yet commenced the tender offer for shares of Span-America stock described in this announcement. Upon commencement of the tender offer, Savaria will file with the U.S. Securities and Exchange Commission (SEC) a tender offer statement on schedule TO and related exhibits, including an offer to purchase, letter of transmittal, and other related documents. Following commencement of the tender offer, Span-America will file with the SEC a solicitation/recommendation statement on Schedule 14D-9. These documents will contain important information about Savaria, Span-America, the transaction, and related matters. Investors and security holders are urged to read each of these documents carefully when they are available. Investors and security holders will be able to obtain free copies of the tender offer statement, the tender offer solicitation/recommendation statement and other documents filed with the SEC by Savaria and Span-America through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain these documents by contacting the information agent named in the tender offer materials.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws. Statements regarding future events and developments and Span-America’s future performance, as well as management’s current expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Forward-looking statements are statements that do not relate strictly to historical or current facts. These statements may include words such as “guidance,” “anticipate,” “estimate,” “expect,” “forecast,” “project,” “plan,” “intend,” “believe,” “confident,” “may,” “should,” “can have,” “likely,” “future” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.

Examples of such statements in this press release include without limitation statements regarding the planned completion of the tender offer and the merger described above. These forward-looking statements are subject to a number of risks and uncertainties. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: (a) uncertainties as to the percentage of Span-America’s stockholders tendering their shares in the tender offer, (b) the possibility that competing offers will be made, (c) the possibility that various closing conditions for the tender offer or the merger may not be satisfied or waived, including that a governmental entity may prohibit or delay the consummation of the merger, (d) the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, vendors and other business partners, (e) the risk that stockholder or other litigation in connection with the tender offer or the merger may result in significant costs of defense, indemnification and liability, (f) the inability to achieve anticipated sales growth in the medical and custom products segments, (g) the possibility of a loss of a key customer or distributor for our products, (h) risks related to international operations and foreign currency exchange associated with Span-America’s Canadian subsidiary, (i) the possibility of having material uncollectible receivables from one or more key customers or distributors, (j) the potential for volatile pricing conditions in the market for polyurethane foam, (k) raw material cost increases, (l) the possibility that some or all of our medical products could be determined to be subject to the 2.3% medical device excise tax imposed by the Affordable Care Act, (m) the potential for lost sales due to competition from low-cost foreign imports, (n) changes in relationships with large customers or key suppliers, (o) uncertainty about whether or not we will be awarded or continue to be awarded one-time seasonal promotions with major retailers, which can have a large impact on annual revenues and earnings, (p) the impact of competitive products and pricing, (q) government reimbursement changes in the medical market, (r) FDA and Health Canada regulation of medical device manufacturing, and (s) other risk factors detailed in Span-America’s Annual Report on Form 10-K for the fiscal year ended October 1, 2016 and other filings with the SEC, which can be found at the SEC’s website www.sec.gov.

We disclaim any obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise. We are not responsible for changes made to this document by wire services or Internet services.

Span-America Medical Systems, Inc.
Jim Ferguson, 864-288-8877, ext. 6912
President and Chief Executive Officer

$MTBC Develops HIE Interfaces Between its Clinical Platforms and Leading Hospitals

$RCON Subsidiary Qualifies for China’s Preferential Income Tax Rate

BEIJING, April 28, 2017  — Recon Technology, Ltd. (NASDAQ: RCON), (“Recon” or the “Company”), a leading independent oilfield services provider operating primarily in China, today announced the Company’s wholly-owned subsidiary, Nanjing Recon Technology Co. Ltd. (“Nanjing Recon”) has received a renewed National High-Tech Enterprise status and certification by the Science and Technology Department of Jiangsu Province.

The National High-Tech Enterprise status allows Nanjing Recon to benefit from a reduced corporate income tax rate of 15%, compared to 25% for companies without the national high-tech status. Nanjing Recon first received this status in 2009, and has since been renewed on three occasions. This renewed National High-Tech Enterprise status allows the Company to continue to receive the preferential income tax rate treatment until 2019.

Management Commentary

Mr. Shenping Yin, Chairman and CEO of Recon stated, “We are pleased to receive the renewed National High-Tech Enterprise status and to continue benefitting from the reduced corporate income tax rate. The other subsidiary of the Company, Beijing BHD Petroleum Technology, Ltd, has also qualified as a National High-Tech enterprise since 2009. We believe it reflects Recon’s commitment to technological advancement, and we continue to invest in enhancing our automation services and solutions.  Research and development remains an integral part of our long-term development strategy, as we feel that it separates Recon from our lesser capitalized competitors and improves our value proposition to our customer base throughout China.”

About China’s National High-Tech Enterprises

The certification of National High-Tech Enterprises was started in the early 1990s in order to establish China’s high-tech industry and promote the rapid development of high tech enterprises. The State Council issued “conditions and measures of the high and new technology enterprises in National High Tech Industrial Development Zone (Guo Fa [1991] No. 12)” in 1991 and authorized the State Science and Technology Commission to organize High-Tech Enterprises of National High-Tech Industrial Development Zone. It set up a series of preferential policies in tax, financial and trade to support the development of High-Tech Enterprises.

About Recon Technology, Ltd. (NASDAQ: RCON)

Recon Technology, Ltd. is China’s first listed non-state owned oil and gas field service company on NASDAQ. Recon supplies China’s largest oil exploration companies, Sinopec (NYSE:SNP) and CNPC, with advanced automated technologies, efficient gathering and transportation equipment and reservoir stimulation measure for increasing petroleum extraction levels, reducing impurities and lowering production costs. Through the years, RCON has taken leading positions on several segmented markets of the oil and gas filed service industry. RCON also has developed stable long-term cooperation relationship with its major clients, and its products and service are also well accepted by clients. For additional information please visit us at www.recon.cn.

Safe Harbor

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

$BLDP Signs Further Follow-On Technology Solutions Agreement With Global Auto OEM

VANCOUVER, April 28, 2017 – Ballard Power Systems (NASDAQ: BLDP; TSX: BLDP) today announced that it has signed a follow-on Technology Solutions contract with an unnamed leading global automotive OEM, further to the contract extension signed and announced on July 20, 2016. Under the new contract extension, Ballard will continue to provide expertise in proton exchange membrane (PEM) fuel cell technology to advance the customer’s membrane electrode assembly (MEA) development program related to future versions of its engine for fuel cell vehicles.

“We continue to see increased levels of fuel cell activity from major OEMs throughout the global automotive industry,” said Randy MacEwen, Ballard’s President and Chief Executive Officer. “At Ballard, we are uniquely positioned to offer these companies bundled Technology Solutions with access to our leading intellectual capital and intellectual property focused on PEM fuel cell technology. These opportunities provide high value to our customers and long-term embedded optionality for Ballard shareholders.”

Dr. Kevin Colbow, Ballard’s Vice President, Technology and Product Development added, “This latest follow-on contract reflects our customer’s satisfaction with the measured progress we have made during the 2014-16 period to provide compelling solutions for challenging technical issues. This next phase of our collaboration with this partner sets a clear roadmap for Ballard technology being integrated into future generations of their fuel cell vehicle platforms.”

About Ballard Power Systems
Ballard Power Systems (NASDAQ: BLDP; TSX: BLDP) provides clean energy products that reduce customer costs and risks, and helps customers solve difficult technical and business challenges in their fuel cell programs. To learn more about Ballard, please visit www.ballard.com.

This release contains forward-looking statements concerning market demand for our products and services. These forward-looking statements reflect Ballard’s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any such forward-looking statements are based on Ballard’s assumptions relating to its financial forecasts and expectations regarding its product development efforts, manufacturing capacity, and market demand.

These statements involve risks and uncertainties that may cause Ballard’s actual results to be materially different, including general economic and regulatory changes, detrimental reliance on third parties, successfully achieving our business plans and achieving and sustaining profitability. For a detailed discussion of these and other risk factors that could affect Ballard’s future performance, please refer to Ballard’s most recent Annual Information Form. Readers should not place undue reliance on Ballard’s forward-looking statements and Ballard assumes no obligation to update or release any revisions to these forward looking statements, other than as required under applicable legislation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.  The Ballard Common Shares have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

$MYSZ Exceeds 200,000 Downloads of Smart Measurement Application SizeUp

AIRPORT CITY, Israel, April 28, 2017  —

MySize Inc. (the “Company”) (NASDAQ: MYSZ; TASE: MYSZ), developer of proprietary, smartphone measurement applications, announced today that the Company is progressing well and continues on its leadership path in ecommerce, having crossed the 200,000 mark in downloads of its flagship product SizeUp, a smart measuring tape.

Since its first introduction in September 2015, there have been 216,192 downloads of SizeUp, with an average of 700 downloads a day, following the launch of SizeUp DIY on January 5, 2017 at CES.

“This rate of growth in the number of downloads indicates that SizeUp DIY is becoming a standard and ‘a must have’ for iOS users, just like the flashlight and other daily required tools. We are thrilled that so many people are already benefiting from SizeUp, and hope the same for many more, especially when we introduce the Android version, which is coming soon,” said CEO Ronen Luzon.

SizeUp enables users to instantly and accurately measure a flat object, by moving the Smartphone from one side of an object to the other. Measurements can be taken in either inches or centimeters.

Click here to view a short video illustrating just how SizeUp DIY ‘measurement from the air’ makes shopping easier and more fun than ever.

Click here to download the SizeUp DIY measurement from the air app.

About MySize Inc.

MySize Inc. (TASE: MYSZ) (NASDAQ: MYSZ) has developed a unique measurement technology based on sophisticated algorithms and cutting edge technology with broad applications including apparel industry, e-commerce, shipping and parcel industry measurement.  This proprietary technology is driven by several patent-pending algorithms which are able to calculate and record measurements in a variety of novel ways. To learn more about MySize, please visit our website. www.mysizeid.com.

Follow us on Facebook, LinkedIn and Twitter.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements.  All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected in or suggested by the forward-looking statements are reasonable, we can give no assurance that these plans, objectives, expectations or intentions will be achieved.  Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and present expectations or projections.  Known material factors that could cause actual results to differ materially from those in the forward-looking statements include: an active trading market for our common stock may not develop on NASDAQ; the trading price for our common stock may fluctuate significantly; and the Company will continue to be a “controlled company,” as defined under NASDAQ rules, and the interests of our controlling stockholder may differ from those of our public stockholders.  Forward-looking statements also are affected by the risk factors described in the Company’s filings with the U.S. Securities and Exchange Commission.  Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Press Contact
Marjie Hadad
MH Communications
marjierhadad@gmail.com
+972-54-536-5220

$REGN & $SNY Announce Kevzara® (sarilumab) Biologics License Application Accepted

New action date for Kevzara U.S. BLA is May 22, 2017

TARRYTOWN, N.Y. and PARIS, April 28, 2017 — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has accepted the resubmission of the Biologics License Application for Kevzara (sarilumab) as a Class I response with a two month review timeline. Per the Prescription Drug User Fee Act (PDUFA), the new target action date is May 22, 2017. Kevzara is an investigational human monoclonal antibody directed against the IL-6 receptor being evaluated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate.

The companies recently received a positive opinion for Kevzara from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), and the European Commission (EC) is expected to make a final decision on the Marketing Authorization Application (MAA) for Kevzara in the European Union in the coming months. In Canada, Kevzara is approved for use in adult patients with moderately to severely active RA who have had an inadequate response or intolerance to one or more biologic or non-biologic DMARDs. The companies are also seeking approvals in a number of other countries globally.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol, atopic dermatitis and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter 

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the clinical development of and potential marketing approvals for the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will be” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development of the product, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve the product  as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of the product, the absence of guarantee that the product if approved will be commercially successful, risks associated with intellectual property, future litigation, the future approval and commercial success of therapeutic alternatives, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. 

Regeneron Forward-Looking Statements and Use of Digital Media
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron’s products, product candidates, and research and clinical programs now underway or planned, including without limitation Kevzara^® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis or other potential indications; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron’s late-stage product candidates, such as Kevzara (including possible regulatory approval of Kevzara by the U.S. Food and Drug Administration based on the Biologics License Application discussed in this news release); the impact of the opinion adopted by the European Medicine Agency’s Committee for Medicinal Products for Human Use discussed in this news release on the European Commission’s decision regarding the Marketing Authorization Application for Kevzara in the European Union; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s product candidates in clinical trials, such as Kevzara; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s products and product candidates, such as Kevzara; ongoing regulatory obligations and oversight impacting Regeneron’s marketed products, research and clinical programs, and business, including those relating to patient privacy; competing drugs and product candidates that may be superior to Regeneron’s products and product candidates; uncertainty of market acceptance and commercial success of Regeneron’s products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron’s products and product candidates, including without limitation Kevzara; the ability of Regeneron’s collaborators, suppliers, or other third parties to perform filling, finishing, packaging, labelling, distribution, and other steps related to Regeneron’s products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer HealthCare LLC, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation relating to Praluent^® (alirocumab) Injection, the permanent injunction granted by the United States District Court for the District of Delaware that, if upheld on appeal, would prohibit Regeneron and Sanofi from marketing, selling, or commercially manufacturing Praluent in the United States, the outcome of any appeals regarding such injunction, the ultimate outcome of such litigation, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2016. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

$HYGS Announces US$21 million Private Placement

MISSISSAUGA, Ontario, April 28, 2017 — Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) (the “Company” or “Hydrogenics”), a leading developer and manufacturer of hydrogen generation and hydrogen-based fuel cell modules, today announced that it has entered into a subscription agreement with Fuzhou Bonded Zone Hejili Equity Investment Limited Partnership (“Hejili”) to issue 2,682,742 common shares of Hydrogenics to Hejili on a private placement basis, for gross proceeds to Hydrogenics of US$21,000,000 (the “Private Placement”) or approximately US$7.83 per common share. The subscription price represented a 10% premium to the 20 day volume-weighted average trading price of the Company’s common shares on the NASDAQ for the period ending April 27, 2017. Hydrogenics intends to use the proceeds of the Private Placement for general corporate purposes. Following Completion of the Private Placement, Hejili’s interest in Hydrogenics will be approximately 17.6%.

The subscription agreement provides, among other things, that Hejili will have pre-emptive rights and the right to nominate one director to the board of directors of Hydrogenics, and that Hejili will be subject to certain restrictions, including lock-up, transfer and voting restrictions, subject, in each case, to certain ownership threshold requirements.

The subscription agreement also provides that Hejili will cooperate with Hydrogenics to jointly develop the Chinese market for hydrogen, energy storage and fuel cell products.

The Private Placement is subject to certain closing conditions, including the receipt of all applicable stock exchange approvals and Chinese regulatory approvals.  The outside date, after which either the Company or Hejili can terminate the subscription agreement if closing has not occurred by such date, is June 12, 2017, subject to two 15 day extensions at the option of the Company.  There can be no assurance that the Chinese regulatory approvals will be obtained before the outside date or at all.

The material change report and subscription agreement will be filed by Hydrogenics on SEDAR and EDGAR.

GMP Securities Asia Limited acted as advisors to Hydrogenics on the Private Placement.  Hawkbridge Capital and Northeast Securities acted as advisors to Hejili on the Private Placement.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The securities will not be and have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold into the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act), absent registration or an exemption from registration requirements. The securities have not been and will not be qualified for sale by way of a prospectus under Canadian securities laws.

About Hydrogenics
Hydrogenics Corporation (www.hydrogenics.com) is a world leader in engineering and building the technologies required to enable the acceleration of a global power shift. Headquartered in Mississauga, Ontario, Hydrogenics provides hydrogen generation, energy storage and hydrogen power modules to its customers and partners around the world. Hydrogenics has manufacturing sites in Germany, Belgium and Canada and service centers in Russia, Europe, the US and Canada.

About Hejili
Headquartered in Fuzhou, Fujian province, China, Fuzhou Bonded Zone Hejili Equity Investment Limited Partnership is a limited partnership founded in 2016.  Hejili’s partners include Fujian Snowman Co., Ltd. (SZSE:002639), Ningbo Meishan Bonded Zone Mingde Investment Partnership, Ningbo Meishan Bonded Zone Mingde Investment Partnership, and Snow-Hydro Industrial Investment Management Ltd.

Forward-looking Statements
This release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, and under applicable Canadian securities law. These statements are based on management’s current expectations and actual results may differ from these forward-looking statements due to numerous factors. Readers should not place undue reliance on Hydrogenics’ forward-looking statements. Investors are encouraged to review the section captioned “Risk Factors” in Hydrogenics’ regulatory filings with the Canadian securities regulatory authorities and the US Securities and Exchange Commission for a more complete discussion of factors that could affect Hydrogenics’ future performance. Furthermore, the forward-looking statements contained herein are made as of the date of this release, and Hydrogenics undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, unless otherwise required by law. The forward-looking statements contained in this release are expressly qualified by this.

Investor Contacts:
Bob Motz, Chief Financial Officer
(905) 361-3660
investors@hydrogenics.com

Chris Witty
Hydrogenics Investor Relations
(646) 438-9385
cwitty@darrowir.com

$SVRA Announces Closing Of Merger With $MSTX

Commences Trading on Nasdaq Capital Market on April 28, 2017 Under Ticker Symbol “SVRA” Conference Call Scheduled for Tuesday May 2nd, 2017 at 4:30 p.m. ET / 3:30 p.m. CT

AUSTIN, Texas, April 27, 2017  — Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the closing of its previously announced merger with Mast Therapeutics, Inc. (NYSE MKT: MSTX), under which the stockholders of Savara have become the majority owners of Mast, and the operations of Mast and Savara have combined. The post-merger company, named Savara Inc., is based in Austin, TX and features three inhaled product candidates, each in advanced stages of clinical development. The company will be led solely by Savara’s current management team. Two independent members of the Mast board remain on the post-merger board together with all five members of the Savara board. Savara’s common stock will commence trading on April 28^th, 2017 on the Nasdaq Capital Market under the trading symbol “SVRA”.

“Savara’s transition to the public market marks a significant milestone for us, and serves as testament to the determination of our team as well as the support of our investors to date,” stated Rob Neville, Chairman and CEO of Savara. “Savara’s team is passionate about helping those who suffer from rare and debilitating lung diseases and will dynamically pursue opportunities to develop impactful products to treat such conditions. We believe Savara presents an attractive business opportunity with our pipeline of unique products with considerable market potential, as well as significant value-driving clinical milestones.”

Savara began the development of AeroVanc in 2010 and is now in preparation for a pivotal Phase 3 study. In July 2016, Savara acquired Serendex Pharmaceuticals adding Molgradex to its pipeline. Molgradex is currently in Phase 2/3 development. With the closing of the Mast merger, Savara adds the Aironite program to its pipeline (also known as AIR001). Savara intends to continue its growth strategy focused on indication expansion, strategic development partnerships and product acquisitions.

In connection with the closing of the merger, Mast effected a 1 for 70 reverse split of its common stock. Post-merger and post-reverse split, Savara has approximately 15 million shares of common stock issued and outstanding with prior Savara stockholders collectively owning approximately 77% of the combined company, and prior Mast stockholders collectively owning approximately 23% of the combined company. Prior to the merger closing, Savara stockholders exercised certain previously issued warrants to purchase Savara shares and invested additional capital into the company, resulting in aggregate net proceeds of approximately $4 million.

Savara’s pipeline now includes:

• Molgradex, an inhaled nebulized GM-CSF to treat pulmonary alveolar proteinosis (PAP) currently in Phase 2/3 development;
• AeroVanc, an inhaled dry-powder vancomycin to treat chronic methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection in cystic fibrosis (CF) in preparation for a pivotal Phase 3 study; and
• Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction (HFpEF) currently in Phase 2 development.

Select Development Milestones

• Completing negotiations with the U.S. Food and Drug Administration (FDA) on the requirements for a pivotal clinical study of Molgradex in the U.S. in Q2/2017;
• Initiating a pivotal Phase 3 study of AeroVanc in Q3/2017;
• Announcing an indication expansion strategy of Molgradex for the treatment of a rare lung infection in Q3/2017;
• Announcing top-line results from a Phase 2/3 study of Molgradex, expected to be registration-enabling in Europe and Japan, in Q1/2018; and
• Announcing results from an ongoing Phase 2 study of Aironite being conducted by the Heart Failure Clinical Research Network in H1/2018.

Conference Call and Webcast

Savara will hold a conference call on Tuesday May 2^nd, 2017, at 4:30 p.m. Eastern Time / 3:30 p.m. Central Time to provide an overview and business update. Interested parties may access the conference call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from outside the U.S. and should request the Savara Inc. Call. A live webcast of the conference call will be available online from the Investors section of Savara’s website at http://www.savarapharma.com/investors/events/. Replays of the webcast will be available on Savara’s website for 30 days and a telephone replay will be available through May 9^th, 2017 by dialing (877) 344-7529 from the U.S., (855) 669-9658 from Canada, and (412) 317-0088 from elsewhere outside the U.S. and entering replay access code 10104600.

About Savara

Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara’s pipeline comprises AeroVanc, a Phase 3 ready inhaled vancomycin, Molgradex, a Phase 2/3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF and Aironite, an inhaled nebulized sodium nitrite solution to treat HFpEF. Savara’s strategy involves expanding its pipeline of best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, creating and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)

Forward Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited to, statements regarding dynamically pursuing opportunities to develop impactful products, Savara presenting an attractive business opportunity with a pipeline of unique products with considerable market potential, as well as significant value-driving clinical milestones, Savara’s intent to continue its growth strategy focused on indication expansion, strategic development partnerships and product acquisitions, Savara’s pipeline and select developmental milestones. Savara may not actually achieve any of the matters referred to in such forward looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs, the timing and ability of Savara to raise additional equity capital to fund continued operations; the ability to successfully develop Savara’s product candidates, and the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates that are safe and effective for use as human therapeutics. Risks and uncertainties facing Savara are described more fully in Savara’s filings with the Securities and Exchange Commission including the most recent Form 8-K filed on April 27, 2017, other filings on Form 8-K, the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Registration Statement on Form S-4 related to the Mast/Savara merger. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes any obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

$PBNC Expands in North Carolina, via Acquisition of Paragon

SUFFOLK, Va. and RALEIGH, N.C., April 27, 2017 — Hampton Roads based TowneBank  (NASDAQ:TOWN) and Raleigh based Paragon Commercial Corporation, the parent company of Paragon Commercial Bank (“Paragon”) (NASDAQ:PBNC), today announced the signing of a definitive merger agreement pursuant to which TowneBank will acquire Paragon creating a $9.7 billion community bank. The acquisition of Paragon will expand Towne’s community banking franchise into two of the fastest growing metropolitan areas in the United States, Charlotte and Raleigh, North Carolina adding to Towne’s current presence in the Norfolk-Virginia Beach Virginia MSA, the Richmond Virginia MSA and Northeastern North Carolina.

Based on financial data as of March 31, 2017, the combined company would have total assets of $9.7 billion, total loans of $7.1 billion and total deposits of $7.5 billion. On a pro forma basis, TowneBank will possess the second largest deposit market share among community banks operating in the demographically attractive Raleigh, North Carolina MSA. In addition, the pro forma entity will have an established and scalable loan and deposit platform in the Charlotte, North Carolina marketplace.

Under the terms of the merger agreement, common shareholders of Paragon will receive a fixed exchange ratio of 1.7250 shares of TowneBank common stock for each outstanding share of Paragon common stock.  This implies a deal value per share of $59.25 or approximately $323.7 million based on TowneBank’s closing stock price of $34.35 on April 26, 2017.  Pending customary regulatory and shareholder approvals, the merger is scheduled to close in the fourth quarter of 2017.

Towne plans to operate in the Raleigh, Charlotte, and Cary markets as Paragon Bank, a division of TowneBank.  Robert C. Hatley, President and CEO of Paragon, will continue in his current role as the President and CEO of the Paragon Division as well as the President of Towne’s North Carolina operations.  Hatley and Paragon Board Chairman, Howard Jung, will join the TowneBank corporate board.

The Paragon Executive Management team consisting of Matthew C. Davis, Executive Vice President and Chief Operating Officer, James F. Fielding, Senior Vice President and Chief Credit Officer, Brian K. Reid, Triangle Market President and Phillip R. Jurney, Charlotte Market President, will continue in their current Paragon roles.

“We are really excited to welcome the extraordinarily talented Paragon team into our Towne family,” said G. Robert Aston, Jr., Chairman and CEO of TowneBank.  “From our humble beginnings in 1999, both Towne and Paragon have prospered through a caring culture of serving others and enriching lives while continuing to build a great community asset for the communities we serve.”

“We have had great admiration for the TowneBank team for many years and have been impressed by the way they’ve grown their franchise into one of the top community banks in Virginia and North Carolina,” stated Robert C. Hatley, President and CEO of Paragon. “We believe partnering with TowneBank will provide us with a strong foundation and additional capacity to deliver our unique private banking experience business model to businesses, professionals, executives and entrepreneurs in our target markets. We expect this merger will be a truly great outcome for our shareholders and will position us for continued success.”

Extensive due diligence was performed over a multi-week period leading up to the merger. Under the proposed merger terms, and inclusive of estimated expenses associated with crossing $10 billion in total assets, the acquisition of Paragon is expected to be immediately accretive to TowneBank’s earnings in 2018 and also thereafter. In addition, the transaction is expected to be nominally dilutive, less than 1%, to TowneBank’s tangible book value at closing. TowneBank’s capital ratios are expected to continue to exceed well-capitalized regulatory standards.

An investor presentation outlining the transaction is provided on the TowneBank website at www.townebank.com under “Investor Relations”.

Sandler O’Neill + Partners, LP acted as financial advisor to TowneBank and Williams Mullen acted as its legal advisor in the transaction.  Raymond James & Associates, Inc. acted as financial advisor to Paragon and Wyrick Robbins Yates & Ponton LLP acted as its legal advisor.

About TowneBank

As one of the top community banks in Virginia and North Carolina, TowneBank operates 37 banking offices serving Chesapeake, Chesterfield County, Glen Allen, Hampton, James City County, Mechanicsville, Newport News, Norfolk, Portsmouth, Richmond, Suffolk, Virginia Beach, Williamsburg, and York County in Virginia, along with Moyock, Grandy, Camden County, Southern Shores, Corolla and Nags Head in North Carolina. Towne also offers a full range of financial services through its controlled divisions and subsidiaries that include Towne Investment Group, Towne Insurance Agency, Towne Benefits, TowneBank Mortgage, TowneBank Commercial Mortgage, Berkshire Hathaway HomeServices Towne Realty, Towne 1031 Exchange, LLC, and Beach Properties of Hilton Head. Local decision-making is a hallmark of its hometown banking strategy that is delivered through the leadership of each group’s President and Board of Directors.  With total assets of $8.2 billion as of March 31, 2017, TowneBank is one of the largest banks headquartered in Virginia.

About Paragon

Paragon Commercial Corporation is the parent company of Paragon Bank, which provides a private banking experience to businesses, professionals, executives, entrepreneurs and other individuals. Founded in Raleigh, North Carolina in 1999, Paragon Bank provides banking services through highly responsive professionals, an extensive courier service, online and mobile technologies, free worldwide ATM access and a select number of strategically placed offices in Raleigh, Cary and Charlotte, North Carolina.

Additional Information and Where to Find It

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the merger, Paragon will file with the Securities and Exchange Commission (“SEC”) a preliminary proxy statement. Paragon will deliver a definitive proxy statement/prospectus to its stockholders seeking approval of the merger and related matters. In addition, each of TowneBank and Paragon may file other relevant documents concerning the proposed merger with the Federal Deposit Insurance Corporation (“FDIC”) and SEC.

Paragon stockholders are strongly urged to read the definitive proxy statement/prospectus regarding the proposed merger when it becomes available and other relevant documents filed with the FDIC and SEC, as well as any amendments or supplements to those documents, because they will contain important information about TowneBank, Paragon and the proposed merger. Free copies of the definitive proxy statement/prospectus, as well as other filings containing information about Paragon, may be obtained after their filing at the SEC’s website (http://www.sec.gov). In addition, free copies of the definitive proxy statement/prospectus, when available, also may be obtained by directing a request by telephone or mail to Paragon Commercial Corporation, 3535 Glenwood Avenue, Raleigh, North Carolina 27612, Attention: Investor Relations (telephone: (919) 788-7770), or by accessing the Paragon’s website at https://www.paragonbank.com under “About Us—Investor Relations.”

Paragon, TowneBank and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Paragon’s stockholders in connection with the proposed merger. Information about the directors and executive officers of Paragon and TowneBank and other persons who may be deemed participants in the solicitation, including their interests in the merger, will be included in the definitive proxy statement/prospectus when it becomes available. Additional information about Paragon’s executive officers and directors can be found in Paragon’s final prospectus filed with the SEC on June 17, 2016. Additional information regarding TowneBank’s executive officers and directors can be found in TowneBank’s definitive proxy statement in connection with its 2017 Annual Meeting of Stockholders filed with the FDIC on April 21, 2017. You may obtain free copies of each document from Paragon as described in the preceding paragraph and from TowneBank by directing a request by telephone or mail to TowneBank, 6001 Harbour View Boulevard, Suffolk, Virginia 23425, Attention: Investor Relations (telephone: (757) 638-6794), or by accessing TowneBank’s website at https://townebank.com under “Investor Relations.”  The information on TowneBank’s and Paragon’s websites is not, and shall not be deemed to be, a part of this release or incorporated into other filings either company makes with the FDIC or SEC.

Forward-Looking Statements

Statements made in this release, other than those concerning reported historical financial information, may be considered forward-looking statements, which speak only as of the date of this release and are based on current expectations and involve a number of assumptions. These include statements as to the anticipated benefits of the merger, including future financial and operating results, cost savings and enhanced revenues that may be realized from the merger as well as other statements of expectations regarding the merger and any other statements regarding future results or expectations. Each of TowneBank and Paragon intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and is including this statement for purposes of these safe harbor provisions. The companies’ respective abilities to predict results, or the actual effect of future plans or strategies, is inherently uncertain. Factors which could have a material effect on the operations and future prospects of each of TowneBank and Paragon, and the resulting company, include but are not limited to: the businesses of TowneBank and Paragon may not be integrated successfully or such integration may be more difficult, time-consuming or costly than expected; expected revenue synergies and cost savings from the merger may not be fully realized or realized within the expected timeframe; revenues following the merger may be lower than expected; customer and employee relationships and business operations may be disrupted by the merger; the ability to obtain required regulatory and stockholder approvals, and the ability to complete the merger on the expected timeframe may be more difficult, time-consuming or costly than expected; changes in interest rates, general economic and business conditions; legislative/regulatory changes; the monetary and fiscal policies of the U.S. government, including policies of the U.S. Treasury and the Board of Governors of the Federal Reserve; the quality and composition of the loan and securities portfolios; demand for loan products; deposit flows; competition; demand for financial services in the companies’ respective market areas; the companies’ respective implementation of new technologies and their ability to develop and maintain secure and reliable electronic systems; changes in the securities markets; and changes in accounting principles, policies and guidelines; and other risk factors detailed from time to time in filings made by TowneBank with the FDIC or Paragon with the SEC. TowneBank and Paragon undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise.

For more information contact:
G. Robert Aston, Jr., TowneBank Chairman and CEO, (757) 638-6780
Robert C. Hatley, Paragon Commercial Corporation President and CEO, (919) 534-7400
William B. Littreal, TowneBank Chief Investor Relations Officer and CSO, (757) 638-6813

$DRYS Announces Full Repayment of Last Legacy Commercial Lender

$LTEA Increases Leadership Capability

Virginia Morris appointed as Chief Sales & Marketing Officer Peter Dydensborg appointed as Vice President of Market Development & Sales

$CDXC Announces Strategic Investment Led by Mr. Li Ka-shing

IRVINE, Calif., April 27, 2017  — ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into a securities purchase agreement for the sale of up to $25 million of its common stock in a private placement led by Hong Kong business leader Mr. Li Ka-shing.

Through Horizons Ventures, Mr. Li has invested in many innovative companies in the last decade, including Facebook, Spotify, DeepMind, Siri, Impossible Foods and Modern Meadow. With Horizons Ventures’ strong global presence, the new investment will be able to support future ChromaDex developments in the global marketplace.

Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, “NIAGEN^® has reached an inflection point where top scientists at leading universities and research institutions are fascinated with the compound resulting in over 100 collaborative agreements currently in place. We are now ready to show the world the anti-aging capabilities of NIAGEN^® and are truly honored to have Horizons Ventures as a strategic investor and be associated with their family of prestigious global investments.”

Tony Lau of Horizons Ventures commented, “We see the category of healthy aging as an emerging, high-growth opportunity. We look forward to supporting ChromaDex in developing products in the healthy aging market and expand the market overseas.”

Robert Fried, President, and Chief Strategy Officer of ChromaDex, added, “Mr. Li Ka-shing and Horizons Ventures have an extraordinary track record in identifying momentous innovation.   This is an important milestone for ChromaDex in our mission to be a world leader in the anti-aging space, with emphasis on NIAGEN^® and NAD precursors.”

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), is acting as exclusive placement agent in the private placement.

The shares of common stock being sold in the private placement will not have been registered under the Securities Act of 1933, as amended (the “Act”).  Accordingly, such shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements under the Act.  In connection with the private placement, ChromaDex will enter into a registration rights agreement with the investors.  Additional details about the transaction are included in a Form 8-K filed by ChromaDex concurrently with this release.

About NIAGEN^® Nicotinamide Riboside and NAD+
NIAGEN^® is the world’s first and only commercially available, nature-identical form of nicotinamide riboside (NR). NR is a next-generation form of vitamin B₃ that acts as a potent and bioavailable booster of nicotinamide adenine dinucleotide (NAD+), which is vital to functions that ensure proper cellular and energy metabolism. NAD+ enables the mitochondria – the ‘powerhouses of the cell’ to convert the food we eat into the energy our body needs to sustain all its functions. It is essential for life.

A decade’s worth of pre-clinical research, along with the first published human clinical trial, demonstrate that supplementing with NR effectively boosts NAD+ levels in both animals and people. With six patents issued and more pending, NIAGEN® is a novel ingredient brought to you only by ChromaDex. Its data were reviewed by the US Food and Drug Administration as part of its New Dietary Ingredient (NDI) notification which made it available for use in dietary supplements. NIAGEN^® is also generally recognized as safe (GRAS). For additional information about NIAGEN^®, visit www.Chromadex.com.  For additional information about NR or NAD+, visit www.aboutnr.com.

About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN^® nicotinamide riboside; pTeroPure^® pterostilbene; PURENERGY^®, a caffeine-pTeroPure^® co-crystal; IMMULINA^™, a spirulina extract; and AnthOrigin^™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including, without limitation, statements related to the anticipated proceeds to be received in the private placement, success of Horizons Ventures’ investments, Horizons Ventures’ ability to support future ChromaDex developments in the global marketplace, the innovative qualities of NIAGEN^®, results of the NIAGEN^® studies and their significance, and the anti-aging capabilities of nicotinamide riboside. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations 
949-419-0288
andrewj@chromadex.com

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing 
949-537-4103
breaho@chromadex.com

$EXAS $48.4 Million Q1 Revune, 150 Percent YOY Volume Growth

Gross margin expands to 65 percent during first quarter – Revenue guidance raised to $195-205 million for 2017, from $170-180 million; – Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000; – 10,000 additional providers ordered Cologuard during the first quarter, and insurance coverage expanded to 78 percent.

MADISON, Wis., April 27, 2017 — Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively.

“Our team is proud of the impact we are having on the early detection of colon cancer,” said Kevin Conroy, chairman and CEO of Exact Sciences. “More than 450,000 people have been screened using Cologuard since it was launched, including many patients who had never previously been screened. We believe that increasing patient demand and physician awareness, and Cologuard’s recent inclusion in the Star Ratings position our test well for long-term, sustainable growth.”

About 10,000 health care providers ordered their initial Cologuard test during the first quarter of 2017. Since Cologuard was launched, approximately 70,000 providers have ordered the test through the first quarter of 2017, including approximately 56,000 of the estimated 200,000 active primary care providers in the United States.

As of April 26, 2017, approximately 197 million Americans are members of health plans that cover Cologuard, including 78 percent of those who are indicated for colorectal cancer screening.

First-Quarter Financial Results

Exact Sciences reported total revenues of $48.4 million during the first quarter of 2017, compared to $14.8 million for the same period of 2016. Average recognized revenue per test during the first quarter of 2017 was $485.

Of the revenue recognized in the three months ended March 31, 2017, approximately $4.3 million, or $43 per test, related to the one-time impact of certain payers meeting the company’s revenue recognition criteria for accrual-basis revenue. Revenue was previously recognized on a cash-basis for these payers. Please see the “How We Recognize Revenue” section of the Management’s Discussion and Analysis in our Form 10-Q for additional information related to the change in revenue recognition.

Average cost per test for the first quarter of 2017 was $170, compared to $227 for the same period of 2016. The company’s gross margin improved from 39 percent to 65 percent from the first quarter of 2016 to the same period of 2017. The change in revenue recognition contributed approximately 3 percentage points to the first-quarter 2017 gross margin.

Operating expenses for the first quarter of 2017 were $66.9 million, compared to $53.7 million for the same period in 2016. The increase was due primarily to personnel additions and higher television advertising spending.

For the first quarter of 2017, Exact Sciences reported a net loss of $34.9 million, or $0.32 per share. The company reported a net loss of $47.5 million, or $0.49 per share, for the same period of 2016.

Cash utilization during the first quarter of 2017 was $36.4 million. Exact Sciences ended the first quarter of 2017 with cash, cash equivalents and marketable securities of $274.7 million, compared to $311.1 million at Dec. 31, 2016.

Updated 2017 Outlook

The company anticipates revenue of $195-205 million and completed Cologuard test volume of at least 470,000 tests during 2017. Previous guidance was $170-180 million in revenue and at least 415,000 completed Cologuard tests. For the second quarter, the company anticipates at least 115,000 completed Cologuard tests.

First-Quarter Conference Call & Webcast

Company management will host a conference call and webcast on Thursday, April 27, 2017, at 10 a.m. ET to discuss first-quarter 2017 results. The webcast will be available at www.exactsciences.com. Domestic callers should dial 877-201-0168 and international callers should dial +1-647-788-4901.

An archive of the webcast and a replay of the conference call will be available at www.exactsciences.com or by calling 800-585-8367 domestically or +1-416-621-4642 internationally. The access code for the conference call and replay is 1619923. The conference call, webcast and replay are open to all interested parties.

About Cologuard

Cologuard was approved by the FDA in August 2014 and results from Exact Sciences’ prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the recommendations of the U.S. Preventive Services Task Force (2016) and the American Cancer Society’s (2014) colorectal cancer screening guidelines. Stool DNA is included in the combined screening guidelines of the American Cancer Society / U.S. Multi-Society Task Force/American College of Radiology (2008), the American College of Gastroenterology guidelines (2009) and the National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.cologuardtest.com. Rx Only.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company’s website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payer reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:
Megan Reiss
Exact Sciences Corp.
meganreiss@exactsciences.com
608-535-8815